Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Kohl

Showing results (121-130 of 129) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 129 results.
Bioorganic & Medicinal Chemistry Letters|July 19, 2001
Evaluation of amino acid-based linkers in potent macrocyclic inhibitors of farnesyl-protein transferaseD C Beshore, I M Bell, C J Dinsmore, et al.
Journal of Medicinal Chemistry|August 25, 2001
Design and biological activity of (S)-4-(5-([1-(3-chlorobenzyl)-2-oxopyrrolidin-3-ylamino]methyl)imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltransferase inhibitor with excellent cell potencyI M Bell, S N Gallicchio, M Abrams, et al.
Cancer Discovery|September 13, 2024
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound MutationsJessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Journal of Medicinal Chemistry|June 27, 2008
Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancerChristopher D Cox, Paul J Coleman, Michael J Breslin, et al.
Bioorganic & Medicinal Chemistry Letters|September 7, 2007
Kinesin spindle protein (KSP) inhibitors. Part 7: Design and synthesis of 3,3-disubstituted dihydropyrazolobenzoxazines as potent inhibitors of the mitotic kinesin KSPRobert M Garbaccio, Edward S Tasber, Lou Anne Neilson, et al.
Journal of Medicinal Chemistry|May 31, 2002
3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potencyIan M Bell, Steven N Gallicchio, Marc Abrams, et al.
Cancer Discovery|October 3, 2019
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular CarcinomaRichard D Kim, Debashis Sarker, Tim Meyer, et al.
Cancer Research|September 15, 2020
Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward OsimertinibYuting Sun, Brooke A Meyers, Barbara Czako, et al.
Science (New York, N.Y.)|December 22, 2012
Radar-enabled recovery of the Sutter's Mill meteorite, a carbonaceous chondrite regolith brecciaPeter Jenniskens, Marc D Fries, Qing-Zhu Yin, et al.
Pageof 13

Showing results (121-130 of 129) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 129 results.
Bioorganic & Medicinal Chemistry Letters|July 19, 2001
Evaluation of amino acid-based linkers in potent macrocyclic inhibitors of farnesyl-protein transferaseD C Beshore, I M Bell, C J Dinsmore, et al.
Journal of Medicinal Chemistry|August 25, 2001
Design and biological activity of (S)-4-(5-([1-(3-chlorobenzyl)-2-oxopyrrolidin-3-ylamino]methyl)imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltransferase inhibitor with excellent cell potencyI M Bell, S N Gallicchio, M Abrams, et al.
Cancer Discovery|September 13, 2024
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound MutationsJessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Journal of Medicinal Chemistry|June 27, 2008
Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancerChristopher D Cox, Paul J Coleman, Michael J Breslin, et al.
Bioorganic & Medicinal Chemistry Letters|September 7, 2007
Kinesin spindle protein (KSP) inhibitors. Part 7: Design and synthesis of 3,3-disubstituted dihydropyrazolobenzoxazines as potent inhibitors of the mitotic kinesin KSPRobert M Garbaccio, Edward S Tasber, Lou Anne Neilson, et al.
Journal of Medicinal Chemistry|May 31, 2002
3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potencyIan M Bell, Steven N Gallicchio, Marc Abrams, et al.
Cancer Discovery|October 3, 2019
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular CarcinomaRichard D Kim, Debashis Sarker, Tim Meyer, et al.
Cancer Research|September 15, 2020
Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward OsimertinibYuting Sun, Brooke A Meyers, Barbara Czako, et al.
Science (New York, N.Y.)|December 22, 2012
Radar-enabled recovery of the Sutter's Mill meteorite, a carbonaceous chondrite regolith brecciaPeter Jenniskens, Marc D Fries, Qing-Zhu Yin, et al.
Pageof 13